Hygroton

Chlortalidone, the active ingredient in Hygroton, is a thiazide‑like diuretic presented as an oral tablet for oral use. It is employed to manage hypertension, edema and heart failure in adult patients.

GNH USA supplies Hygroton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Chlortalidone is indicated for conditions that involve excess fluid retention or elevated blood pressure. - Hypertension: helps lower systolic and diastolic blood pressure to reduce cardiovascular risk. - Edema: promotes removal of excess fluid, decreasing swelling in peripheral tissues. - Heart failure: assists in reducing preload and afterload, supporting symptomatic relief and improved cardiac output.

Adverse reactions may occur with any diuretic therapy.

Common Side Effects: - Increased urination: more frequent need to void. - Electrolyte imbalance: low potassium or sodium levels. - Dizziness or light‑headedness, especially on standing. - Headache. - Elevated blood glucose in susceptible individuals.

Serious or Rare Side Effects: - Severe dehydration or hypovolemia. - Acute kidney injury. - Hyponatremia with neurological symptoms. - Allergic skin reactions such as rash or pruritus. - Blood dyscrasias including leukopenia or thrombocytopenia.

Before initiating therapy, consider patient‑specific factors and monitoring requirements. - Renal function: assess creatinine clearance and adjust if impaired. - Electrolytes: monitor potassium, sodium, and magnesium regularly. - Diabetes: watch for worsening glycemic control. - Gout: be aware of potential uric acid elevation. - Pregnancy and lactation: use only if benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Chlortalidone can alter the pharmacokinetics or pharmacodynamics of several agents.

Major Interactions (Avoid): - Lithium: increased lithium levels may cause toxicity. - NSAIDs: may reduce diuretic efficacy and impair renal function. - ACE inhibitors/ARBs: heightened risk of potassium loss and renal impairment.

Moderate Interactions (Monitor Closely): - Antidiabetic drugs: may require dose adjustment due to altered glucose control. - Digoxin: enhanced risk of digitalis toxicity with electrolyte disturbances. - Corticosteroids: additive sodium retention counteracting diuretic effect.